Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV
Authors:
- Edmund V CapparelliECEdmund V Capparelli
- Diane HollandDHDiane Holland
- Charles OkamotoCOCharles Okamoto
- Bryan GraggBGBryan Gragg
- Janis DurelleJDJanis Durelle
- Jennifer Marquie-BeckJMJennifer Marquie-Beck
- Geoffrey van Den BrandeGBGeoffrey van Den Brande
- Ron EllisRERon Ellis
- Scott LetendreSLScott Letendre
- 10 June 2005
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 19 (9) , 949-952
Abstract
Lopinavir (LPV) is highly bound to plasma proteins and is a substrate for active drugs transporters, which may greatly limit the access of LPV to the central nervous system (CNS). However, even low lopinavir concentrations may be sufficient to inhibit HIV replication. Prior anecdotal reports indicated that lopinavir concentrations were below detection in cerebrospinal fluid (CSF). LPV was measured by liquid chromatography/mass spectrometry in 31 CSF–plasma pairs from 26 HIV-infected individuals who were taking LPV-containing antiretroviral regimens. The lower limit of quantification was 3.7 μg/l. Seven of the sample pairs had very low plasma (and CSF) LPV concentrations, with a mean estimated plasma trough of 274 μg/l (range, < 3.7 to 608; typical trough values ∼4000 μg/l), suggesting poor recent adherence. In the remaining 24 sample pairs, the median LPV concentration was 5889 μg/l [interquartile range (IQR), 4805–9620] and all CSF samples had measurable LPV concentrations: median 17.0 μg/l (IQR, 12.1–22.7). The median CSF–plasma ratio was 0.23% (range, 0.12–0.75). All CSF concentrations in these samples were more than double the 50% inhibitory concentration for wild-type HIV virus. In patients with typical plasma levels of LPV, the drug is detectable in the CSF at concentrations that exceed those needed to inhibit HIV replication. Despite being > 98% bound to plasma proteins, LPV penetrates into the CNS and may contribute to the control of HIV in this potential reservoir.Keywords
This publication has 12 references indexed in Scilit:
- Natural Variation of Drug Susceptibility in Wild-Type Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 2004
- Effects of Ritonavir on Indinavir Pharmacokinetics in Cerebrospinal Fluid and PlasmaAntimicrobial Agents and Chemotherapy, 2003
- Lopinavir/RitonavirDrugs, 2003
- Discrepancies between Protease Inhibitor Concentrations and Viral Load in Reservoirs and Sanctuary Sites in Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 2003
- Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: Clinical correlationsHIV Research & Clinical Practice, 2002
- Indinavir Population Pharmacokinetics in Plasma and Cerebrospinal FluidAntimicrobial Agents and Chemotherapy, 2000
- Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavirAIDS, 2000
- Cerebrospinal Fluid HIV RNA and Drug Levels With Combination Ritonavir and SaquinavirJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Cerebrospinal Fluid HIV RNA and Drug Levels With Combination Ritonavir and SaquinavirJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Failure to Detect Nelfinavir in the Cerebrospinal Fluid of HIV-1-Infected Patients With and Without AIDS Dementia ComplexJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999